Santen Pharmaceutical Co., Ltd. (SNPHF)
USD 10.53
(0.0%)
USD 10.53
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -59.42 Billion JPY | -335.94% |
| 2023 | -21.69 Billion JPY | 56.68% |
| 2022 | -50.08 Billion JPY | 5.04% |
| 2021 | -52.74 Billion JPY | 33.32% |
| 2020 | -79.1 Billion JPY | -18.54% |
| 2019 | -66.73 Billion JPY | -8.18% |
| 2018 | -61.68 Billion JPY | -69.61% |
| 2017 | -36.36 Billion JPY | 52.96% |
| 2016 | -77.31 Billion JPY | -168.4% |
| 2015 | -28.8 Billion JPY | 54.6% |
| 2014 | -63.45 Billion JPY | -24.91% |
| 2013 | -50.79 Billion JPY | 23.17% |
| 2012 | -66.12 Billion JPY | -1.09% |
| 2011 | -65.4 Billion JPY | -16.67% |
| 2010 | -56.06 Billion JPY | -53.93% |
| 2009 | -36.41 Billion JPY | -20.57% |
| 2008 | -30.2 Billion JPY | -4.7% |
| 2007 | -28.84 Billion JPY | 0.41% |
| 2006 | -28.96 Billion JPY | -69.75% |
| 2005 | -17.06 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -10.81 Billion JPY | 50.13% |
| 2024 Q4 | -59.42 Billion JPY | -22.76% |
| 2024 FY | -59.42 Billion JPY | -173.89% |
| 2024 Q3 | -48.4 Billion JPY | -57.03% |
| 2024 Q2 | -30.82 Billion JPY | -184.93% |
| 2023 Q3 | -24.12 Billion JPY | 22.21% |
| 2023 Q2 | -31.01 Billion JPY | 32.98% |
| 2023 FY | -21.69 Billion JPY | 56.68% |
| 2023 Q4 | -21.69 Billion JPY | 10.07% |
| 2023 Q1 | -46.27 Billion JPY | 7.61% |
| 2022 Q3 | -46.61 Billion JPY | 16.95% |
| 2022 Q1 | -44.65 Billion JPY | 15.34% |
| 2022 Q2 | -56.12 Billion JPY | -25.68% |
| 2022 Q4 | -50.08 Billion JPY | -7.45% |
| 2022 FY | -50.08 Billion JPY | 5.04% |
| 2021 FY | -52.74 Billion JPY | 33.32% |
| 2021 Q1 | -82.34 Billion JPY | -0.63% |
| 2021 Q2 | -58.74 Billion JPY | 28.66% |
| 2021 Q3 | -52.91 Billion JPY | 9.93% |
| 2021 Q4 | -52.74 Billion JPY | 0.32% |
| 2020 Q3 | -82.59 Billion JPY | 2.8% |
| 2020 Q2 | -84.97 Billion JPY | -25.33% |
| 2020 FY | -79.1 Billion JPY | -18.54% |
| 2020 Q1 | -67.79 Billion JPY | -1.6% |
| 2020 Q4 | -81.82 Billion JPY | 0.93% |
| 2019 Q2 | -75.23 Billion JPY | -30.89% |
| 2019 Q4 | -66.73 Billion JPY | 11.49% |
| 2019 Q3 | -75.39 Billion JPY | -0.21% |
| 2019 FY | -66.73 Billion JPY | -8.18% |
| 2019 Q1 | -57.48 Billion JPY | 6.81% |
| 2018 Q2 | -61.84 Billion JPY | -26.34% |
| 2018 FY | -61.68 Billion JPY | -69.61% |
| 2018 Q4 | -61.68 Billion JPY | -2.73% |
| 2018 Q3 | -60.04 Billion JPY | 2.91% |
| 2018 Q1 | -48.95 Billion JPY | -34.68% |
| 2017 Q1 | -74.51 Billion JPY | 3.64% |
| 2017 FY | -36.36 Billion JPY | 52.96% |
| 2017 Q4 | -36.34 Billion JPY | 24.43% |
| 2017 Q3 | -48.1 Billion JPY | 17.56% |
| 2017 Q2 | -58.34 Billion JPY | 21.7% |
| 2016 Q2 | -108.01 Billion JPY | -92.32% |
| 2016 Q1 | -56.16 Billion JPY | -94.97% |
| 2016 FY | -77.31 Billion JPY | -168.4% |
| 2016 Q4 | -77.33 Billion JPY | 25.69% |
| 2016 Q3 | -104.06 Billion JPY | 3.66% |
| 2015 Q3 | -18.21 Billion JPY | -51.64% |
| 2015 Q4 | -28.8 Billion JPY | -58.15% |
| 2015 FY | -28.8 Billion JPY | 54.6% |
| 2015 Q1 | -57.63 Billion JPY | 9.16% |
| 2015 Q2 | -12.01 Billion JPY | 79.16% |
| 2014 FY | -63.45 Billion JPY | -24.91% |
| 2014 Q4 | -63.45 Billion JPY | -16.29% |
| 2014 Q3 | -54.56 Billion JPY | -3.5% |
| 2014 Q2 | -52.71 Billion JPY | -16.42% |
| 2014 Q1 | -45.27 Billion JPY | 10.86% |
| 2013 FY | -50.79 Billion JPY | 23.17% |
| 2013 Q4 | -50.79 Billion JPY | -7.37% |
| 2013 Q2 | -48.79 Billion JPY | 9.69% |
| 2013 Q3 | -47.31 Billion JPY | 3.04% |
| 2013 Q1 | -54.02 Billion JPY | 18.29% |
| 2012 Q4 | -66.12 Billion JPY | -14.76% |
| 2012 Q3 | -57.61 Billion JPY | 17.68% |
| 2012 Q2 | -69.99 Billion JPY | -10.3% |
| 2012 Q1 | -63.45 Billion JPY | 2.98% |
| 2012 FY | -66.12 Billion JPY | -1.09% |
| 2011 Q3 | -52.84 Billion JPY | 4.23% |
| 2011 FY | -65.4 Billion JPY | -16.67% |
| 2011 Q1 | -49.03 Billion JPY | 12.53% |
| 2011 Q2 | -55.17 Billion JPY | -12.52% |
| 2011 Q4 | -65.4 Billion JPY | -23.77% |
| 2010 Q3 | -49.09 Billion JPY | -1.2% |
| 2010 FY | -56.06 Billion JPY | -53.93% |
| 2010 Q2 | -48.51 Billion JPY | 0.0% |
| 2010 Q4 | -56.06 Billion JPY | -14.2% |
| 2009 Q4 | -36.41 Billion JPY | 0.0% |
| 2009 FY | -36.41 Billion JPY | -20.57% |
| 2008 FY | -30.2 Billion JPY | -4.7% |
| 2007 FY | -28.84 Billion JPY | 0.41% |
| 2006 FY | -28.96 Billion JPY | -69.75% |
| 2005 FY | -17.06 Billion JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.74 Billion USD | 361.206% |
| Bristol-Myers Squibb Company PFD CONV 2 | 30 Billion USD | 298.08% |
| CSPC Pharmaceutical Group Limited | -1.59 Billion USD | -3627.885% |
| Clarus Therapeutics Holdings, Inc. | 15.85 Million USD | 374920.235% |
| Novartis AG | 12.95 Billion USD | 558.695% |
| PT Kalbe Farma Tbk. | -169.7 Million USD | -34916.764% |